Methoxypolyethyleenglycolepoëtine beta

Generic name
Methoxypolyethyleenglycolepoëtine beta
Brand name
ATC Code
B03XA03
Compare …

Methoxypolyethyleenglycolepoëtine beta

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Anemia in chronic kidney disease
  • Intravenous
    • 3 months up to 18 years

      • Children treated with ESA and stable Hb can be converted to methoxypolyethylene glycol-epoetin beta according to the table below.

        Previous weekly dose Darbepoëtine alfa (microgram/week) Previous weekly dose epoëtine (IE/week) Dose methoxypolyethyleenglycolepoëtine beta (microgram once every 4 weeks)
        9-12 2000-2700 30
        12-15 2700-3500 50
        15-24 3500-5500 75
        24-30 5500-6500 100
        30-35 6500-8000 120
        35-47 8000-10.000 150
        47-60 10.000-13.000 200
        60-90 13.000-20.000 250
        ≥ 90 ≥ 20.000 360

        Dose adjustments: Based on effect, increase/decrease dose by 25% every 4 weeks as needed.

        • ALTERNATIVE: Subcutaneous injection. Do retain the chosen route of administration
        • If the hemoglobin level continues to rise after dose reduction, treatment should be interrupted until the hemoglobin level begins to decrease. At that time, treatment should be restarted with a dose 25% lower than the previously administered dose
        • Hemoglobin target value between 10 g/dl (6.2 mmol/l) and 12 g/dl (7.5 mmol/l).

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The safety profile in children is generally similar to that in adults.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In children, especially younger than 1 year of age, evaluate carefully before switching ESA. Stabilize Hb levels before switching to methoxypolyethylene glycol epoetin β. After ESA conversion, check Hb levels every 4 weeks.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER ANTIANEMIC PREPARATIONS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Other antianemic preparations
B03XA02
B03XA01
B03XA01
B03XA01

Reference

  1. Roche Registration GmbH, SmPC Mircera (EU/1/07/400/008) rev 30, 07 -12-2023, www.emea.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose